IMMUNE-ONC THERAPEUTICS
Immune-Onc Therapeutics is a newly established bio-pharmaceutical company that focuses on developing innovative therapeutic antibodies for cancer treatment. The company applies the latest scientific insights and expertise in drug development to advance novel immuno-oncology products and bring new treatment options to cancer patients.
IMMUNE-ONC THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Health Care Medical Therapeutics
Founded:
2016-01-01
Address:
Palo Alto, California, United States
Country:
United States
Website Url:
http://www.immune-onc.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
115.14 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default LetsEncrypt Content Delivery Network Organization Schema Cloudflare JS CDN JS GoDaddy DNS Typekit
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Intellia Therapeutics
Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Current Employees Featured
Founder
Investors List
Sphera Global Healthcare Fund
Sphera Global Healthcare Fund investment in Series B - Immune-Onc Therapeutics
Oceanpine Capital
Oceanpine Capital investment in Series B - Immune-Onc Therapeutics
Northern Light Venture Capital
Northern Light Venture Capital investment in Series B - Immune-Onc Therapeutics
Vivo Capital
Vivo Capital investment in Series B - Immune-Onc Therapeutics
Octagon Capital Advisors
Octagon Capital Advisors investment in Series B - Immune-Onc Therapeutics
Leukemia & Lymphoma Society
Leukemia & Lymphoma Society investment in Series B - Immune-Onc Therapeutics
National Cancer Institute
National Cancer Institute investment in Grant - Immune-Onc Therapeutics
Vivo Capital
Vivo Capital investment in Series B - Immune-Onc Therapeutics
StartX (Stanford-StartX Fund)
StartX (Stanford-StartX Fund) investment in Series B - Immune-Onc Therapeutics
Northern Light Venture Capital
Northern Light Venture Capital investment in Series B - Immune-Onc Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-14 | Immune-Onc Therapeutics Announces Appointment of Christopher Whitmore as Chief Financial Officer and Provides Clinical Progress Update |
Official Site Inspections
http://www.immune-onc.com Semrush global rank: 4.49 M Semrush visits lastest month: 2.39 K
- Host name: 198.185.159.145
- IP address: 198.185.159.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Immune-Onc Therapeutics"
Team - Immune-Onc Therapeutics
Dr. Klencke is an Independent Board Member of Immune-Onc Therapeutics, Inc. and a world-class drug developer and research & development expert, having made significant contributions to the oncology community with the …See details»
Immune-Onc Therapeutics - Org Chart, Teams, Culture & Jobs
View Immune-Onc Therapeutics' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more. This is an unverified …See details»
Immune-Onc Therapeutics - Crunchbase Company Profile & Funding
Immune-Onc Therapeutics is a newly established bio-pharmaceutical company that focuses on developing innovative therapeutic antibodies for cancer treatment. The company applies the …See details»
IC-ONC: Building Local Communities in a Global Network
IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education. Educational …See details»
Immune-Onc Therapeutics, INC - Leukemia & Lymphoma Society
Immune-Onc is a private, clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients. The …See details»
Immune-Onc Therapeutics | Leukemia and Lymphoma Society
Jan 31, 2022 Immune-Onc has a promising pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) of myeloid checkpoints. IO-202 …See details»
Immune-Onc Therapeutics | Leukemia and Lymphoma Society
Mar 30, 2021 Immune-Onc has a promising pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) of myeloid checkpoints. Their …See details»
Immune-Onc Therapeutics Announces $73 Million in Series B1 and …
Mar 30, 2021 Immune-Onc’s research and development programs focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) of myeloid checkpoints to …See details»
Immune-Onc Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Immune-Onc Therapeutics Inc. (“Immune-Onc”) is a private, clinical-stage biopharmaceutical company developing novel therapies in immunology and oncology by targeting myeloid cell …See details»
Immune-Onc Therapeutics Announces Key Executive …
Sep 18, 2018 Song joins Immune-Onc from Genentech where she held positions of increasing responsibility over her 16-year tenure at the company and most recently served as a Senior …See details»
Immune-Onc Therapeutics Announces Close of Series B Extension …
PALO ALTO, CA, January 5, 2023 - Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting …See details»
Immune-Onc Therapeutics Announces Clinical Trial Collaboration …
PALO ALTO, Calif., February 20, 2024--Immune-Onc Therapeutics, Inc. ("Immune-Onc"), a private, clinical-stage biopharmaceutical company dedicated to advancing novel therapies in …See details»
Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, …
Purpose In this first-in-human dose escalation study, the safety and efficacy of IO-108, a fully human monoclonal antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2), …See details»
Immune-Onc Adds $25 Million to B Round for Novel Myeloid …
Immune-Onc Therapeutics added $25 million from China investors to its Series B extension, bringing the total for the B round to $131 million. Immune-Onc is a Palo Alto, CA-Hangzhou …See details»
Pipeline Overview — Immune-Onc Therapeutics
Immune-Onc has established agreements with leading biopharmaceutical companies, including BeiGene and Regeneron, to support its global product development plans for IO-108. A Roche …See details»
Challenges and opportunities in cancer immunotherapy: a Society …
Cancer immunotherapy has flourished over the last 10–15 years, transforming the practice of oncology and providing long-term clinical benefit to some patients. During this time, three …See details»
Immune-Onc Therapeutics Announces $73 Million Financing to …
PALO ALTO, CA, March 30, 2021 / Business Wire / -- Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics …See details»
Immune-Onc Therapeutics Selected for Oral Presentation at …
PALO ALTO, CA, November 5, 2024 -- Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private clinical-stage biopharmaceutical company advancing novel therapies in immunology and …See details»
Immune-Onc Therapeutics | Leukemia and Lymphoma Society
Apr 20, 2021 Immune-Onc has a promising pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) of myeloid checkpoints. Their …See details»
Immune-Onc Therapeutics Announces Clinical Trial Collaboration …
Feb 20, 2024 Immune-Onc has established agreements with leading biopharmaceutical companies, including BeiGene, Regeneron and Roche, to support its global product …See details»